908 Devices (MASS) to Release Quarterly Earnings on Monday

908 Devices (NASDAQ:MASS) is projected to issue its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $13.5780 million for the quarter. 908 Devices has set its FY 2025 guidance at EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

908 Devices (NASDAQ:MASS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%.The business had revenue of $4.70 million during the quarter, compared to the consensus estimate of $12.17 million. On average, analysts expect 908 Devices to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Trading Up 4.6%

NASDAQ MASS opened at $7.98 on Monday. The firm’s fifty day simple moving average is $7.44 and its two-hundred day simple moving average is $6.67. 908 Devices has a 12-month low of $1.81 and a 12-month high of $9.34. The firm has a market capitalization of $286.16 million, a P/E ratio of -14.78 and a beta of 0.45.

Insider Buying and Selling at 908 Devices

In other news, CFO Joseph H. Iv Griffith sold 4,292 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $9.05, for a total transaction of $38,842.60. Following the sale, the chief financial officer directly owned 92,930 shares of the company’s stock, valued at $841,016.50. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 10,000 shares of company stock worth $80,593 over the last 90 days. 23.70% of the stock is owned by insiders.

Institutional Investors Weigh In On 908 Devices

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in shares of 908 Devices by 221.7% during the second quarter. Bank of America Corp DE now owns 363,217 shares of the company’s stock valued at $2,590,000 after buying an additional 250,311 shares during the last quarter. Marshall Wace LLP boosted its holdings in 908 Devices by 359.4% in the second quarter. Marshall Wace LLP now owns 648,796 shares of the company’s stock valued at $4,626,000 after purchasing an additional 507,562 shares during the last quarter. Geode Capital Management LLC boosted its holdings in 908 Devices by 11.7% in the second quarter. Geode Capital Management LLC now owns 658,603 shares of the company’s stock valued at $4,697,000 after purchasing an additional 68,764 shares during the last quarter. Manatuck Hill Partners LLC purchased a new stake in 908 Devices in the second quarter valued at $570,000. Finally, Jane Street Group LLC purchased a new stake in 908 Devices in the second quarter valued at $341,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on MASS shares. Leerink Partners raised shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, October 8th. Leerink Partnrs raised shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 5th. Finally, Wall Street Zen raised shares of 908 Devices from a “sell” rating to a “hold” rating in a report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, 908 Devices currently has an average rating of “Moderate Buy” and an average price target of $8.00.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.